NX-1607 is a small molecule commercialized by Nurix Therapeutics, with a leading Phase I program in Solid Tumor. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of NX-1607’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for NX-1607 is expected to reach an annual total of $7 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
NX-1607 is under development for the treatment of solid tumors including melanoma, epithelial ovarian cancer, gastric cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, metastatic castration resistant prostate cancer, diffuse large b-cell lymphoma with Richter transformation, cervical cancer, metastatic colorectal cancer, fallopian tube cancer, peritoneal cancer, metastatic urothelial cancer, malignant pleural mesothelioma and adenocarcinoma of the gastroesophageal junction. It is administered by oral route. It act by targeting casitas B lineage lymphoma proto-oncogene b (CBL-b). The drug candidate is developed based on DEligase platform.
Nurix Therapeutics Overview
Nurix Therapeutics, formerly Nurix Inc, is a biopharmaceutical company that discovers, develops and commercializes small molecule drugs to treat cancer and autoimmune diseases. It is investigating NX-2127, a Bruton’s tyrosine kinase (BTK) inhibitor against B-cell malignancies; NX-5948 drug for the treatment of B-cell malignancies and autoimmune diseases; NX-1607, a ligase inhibitor for immune-oncology indications; and DeTIL-0255 program targeting tumor infiltrating lymphocytes. The company is also evaluating KINASE-CTM3 against T-cell malignancies and autoimmune diseases; and COVID-CTMs for anti-viral infections. Nurix employs DELigase platform technology to modulate targeted proteins and also destroy disease-causing proteins by harnessing the activity of specific E3 ligases. The company works in collaboration with Sanofi and Gilead Sciences to develop its products. Nurix is headquartered in San Francisco, California, the US.
The company reported revenues of (US Dollars) US$38.6 million for the fiscal year ended November 2022 (FY2022), an increase of 29.8% over FY2021. The operating loss of the company was US$183.9 million in FY2022, compared to an operating loss of US$117.9 million in FY2021. The net loss of the company was US$180.4 million in FY2022, compared to a net loss of US$117.2 million in FY2021.
For a complete picture of NX-1607’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.